71 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
12617894	6	An adjustable release rate linking strategy for cytotoxin-peptide conjugates.	Tulane University Health Sciences Center
26898814	154	SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.	Merck Research Laboratories
26199120	66	Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.	Merck Research Laboratories
26005524	147	Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.	Merck Research Laboratories
25699156	24	Treating pain with somatostatin receptor subtype 4 agonists.	Therachem Research Medilab (India)
25050159	71	Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists.	Merck Research Laboratories
24944745	75	Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.	Merck Research Laboratories
18162395	89	Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst 1 receptor.	Novartis Institutes For Biomedical Research
17507221	58	Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists.	Novartis Institutes For Biomedical Research
24900499	67	The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.	TBA
24900466	55	Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.	TBA
24900340	40	N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.	TBA
20666484	40	Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors.	University Of Firenze
19351180	165	Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.	The Clayton Foundation Laboratories For Peptide Biology
19067538	110	Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities.	Vrije Universiteit Brussel
18543899	171	Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.	University Of Berne
18410084	115	Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.	Salk Institute
18410083	30	Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.	Salk Institute
18210999	21	Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.	University Of Firenze
16220980	43	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.	University Of California San Diego
15828816	100	N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.	Technische Universit£T M£Nchen
15658865	240	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides.	Salk Institute
15982879	61	3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists.	Institut Henri Beaufour
14667213	90	Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.	Salk Institute
14667212	110	Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.	Salk Institute
12477342	27	2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.	Merck Research Laboratories
11312929	90	Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.	Tulane University Health Sciences Center
11520208	45	Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity.	Institut Henri Beaufour
9544214	197	Potent antagonists of somatostatin: synthesis and biology.	Tulane University School Of Medicine
9632348	37	Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists.	Merck Research Laboratories
11327607	67	Novel non-peptide ligands for the somatostatin sst3 receptor.	Institut Henri Beaufour
11266182	53	Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5.	Institut Henri Beaufour
21806016	78	N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.	Salk Institute
20684600	53	Biological diversity from a structurally diverse library: systematically scanning conformational space using a pyranose scaffold.	Alchemia
19786348	261	Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.	F. Hoffmann-La Roche
18020391	12	From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.	F. Hoffmann-La Roche
18020390	37	Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.	F. Hoffmann-La Roche
17559206	22	New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold.	Vrije Universiteit Brussel
16854054	30	Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.	Salk Institute
16722631	87	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.	Predix Pharmaceuticals
15658864	225	Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.	Salk Institute
14667215	64	Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.	Salk Institute
14667214	185	Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.	Salk Institute
11931620	40	Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units.	Hebrew University
11405660	155	Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).	Salk Institute
11311064	84	N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity.	Tulane University Health Sciences Center
11212124	41	Nipecotic and iso-nipecotic amides as potent and selective somatostatin subtype-2 receptor agonists.	Merck Research Laboratories
11133079	10	Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation.	University Of California
10354394	216	Highly potent cyclic disulfide antagonists of somatostatin.	Tulane University School Of Medicine
10091708	32	Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization.	Merck Research Laboratories
9667958	40	Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues.	University Of California San Diego
9554871	43	Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis.	University Of Pennsylvania
26595185	30	Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies.	Government College University
25787859	13	Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.	China Pharmaceutical University
25283372	27	Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.	Northeastern University
19351113	30	Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.	Pfizer
16275085	29	Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.	Wyeth Research
16759091	28	Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.	National Tsing Hua University